Other substances

rSIFN-co

A recombinant cytokine.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

rSIFN-co is a genetically engineered recombinant interferon alpha (Li et al., 2021).

rSIFN-co on DrugBank

Synonyms

Recombinant Super-Compound Interferon

 

Supporting references

Link Tested on Impact factor Notes Publication date
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial
Severe severity Protein factor Randomized controlled single-blind trial Moderate severity 		Patients 3.24

The treatment was associated with better overall clinical improvement, faster radiological improvement, and shorter time to negative viral conversion compared to traditional interferon alpha treatment, with similar adverse effects. Sample size: 46 + 48 interferon alpha (non-engineered) group. Dosage: Nebulized 12 IU twice daily until hospital discharge (but not for more than 28 days). Primary endpoint: Time to clinical improvement on an ordinal scale.



 Feb/23/2021
Export (.csv)